Literature DB >> 22915805

Sensing and control of bluetongue virus infection in epithelial cells via RIG-I and MDA5 helicases.

Emilie Chauveau1, Virginie Doceul, Estelle Lara, Micheline Adam, Emmanuel Breard, Corinne Sailleau, Cyril Viarouge, Alexandra Desprat, Gilles Meyer, Isabelle Schwartz-Cornil, Suzana Ruscanu, Bernard Charley, Stéphan Zientara, Damien Vitour.   

Abstract

Bluetongue virus (BTV), an arthropod-borne member of the Reoviridae family, is a double-stranded RNA virus that causes an economically important livestock disease that has spread across Europe in recent decades. Production of type I interferon (alpha/beta interferon [IFN-α/β]) has been reported in vivo and in vitro upon BTV infection. However, the cellular sensors and signaling pathways involved in this process remain unknown. Here we studied the mechanisms responsible for the production of IFN-β in response to BTV serotype 8. Upon BTV infection of A549 cells, expression of IFN-β and other proinflammatory cytokines was strongly induced at both the protein and mRNA levels. This response appeared to be dependent on virus replication, since exposure to UV-inactivated virus failed to induce IFN-β. We also demonstrated that BTV infection activated the transcription factors IFN regulatory factor 3 and nuclear factor κB. We investigated the role of several pattern recognition receptors in this response and showed that expression of IFN-β was greatly reduced after small-interfering-RNA-mediated knockdown of the RNA helicase encoded by retinoic acid-inducible gene I (RIG-I) or melanoma differentiation-associated gene 5 (MDA5). In contrast, silencing of MyD88, Toll-like receptor 3, or the recently described DexD/H-box helicase DDX1 sensor had no or a weak effect on IFN-β induction, suggesting that the RIG-I-like receptor pathway is specifically engaged for BTV sensing. Moreover, we also showed that overexpression of either RIG-I or MDA5 impaired BTV expression in infected A549 cells. Overall, this indicates that RIG-I and MDA5 can both contribute to the recognition and control of BTV infection.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22915805      PMCID: PMC3486277          DOI: 10.1128/JVI.00430-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  68 in total

Review 1.  Regulation of immune cell homeostasis by type I interferons.

Authors:  Fabrizio Mattei; Giovanna Schiavoni; David F Tough
Journal:  Cytokine Growth Factor Rev       Date:  2010-06-02       Impact factor: 7.638

2.  VISA is an adapter protein required for virus-triggered IFN-beta signaling.

Authors:  Liang-Guo Xu; Yan-Yi Wang; Ke-Jun Han; Lian-Yun Li; Zhonghe Zhai; Hong-Bing Shu
Journal:  Mol Cell       Date:  2005-09-16       Impact factor: 17.970

Review 3.  Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures.

Authors:  Richard E Randall; Stephen Goodbourn
Journal:  J Gen Virol       Date:  2008-01       Impact factor: 3.891

Review 4.  Toll-like receptor and RIG-I-like receptor signaling.

Authors:  Taro Kawai; Shizuo Akira
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

5.  DDX1, DDX21, and DHX36 helicases form a complex with the adaptor molecule TRIF to sense dsRNA in dendritic cells.

Authors:  Zhiqiang Zhang; Taeil Kim; Musheng Bao; Valeria Facchinetti; Sung Yun Jung; Amir Ali Ghaffari; Jun Qin; Genhong Cheng; Yong-Jun Liu
Journal:  Immunity       Date:  2011-06-24       Impact factor: 31.745

6.  RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates.

Authors:  Andreas Pichlmair; Oliver Schulz; Choon Ping Tan; Tanja I Näslund; Peter Liljeström; Friedemann Weber; Caetano Reis e Sousa
Journal:  Science       Date:  2006-10-12       Impact factor: 47.728

7.  Production of interferon by human tumor cell lines.

Authors:  P Jameson; S E Grossberg
Journal:  Arch Virol       Date:  1979       Impact factor: 2.574

8.  The most likely time and place of introduction of BTV8 into Belgian ruminants.

Authors:  Claude Saegerman; Philip Mellor; Aude Uyttenhoef; Jean-Baptiste Hanon; Nathalie Kirschvink; Eric Haubruge; Pierre Delcroix; Jean-Yves Houtain; Philippe Pourquier; Frank Vandenbussche; Bart Verheyden; Kris De Clercq; Guy Czaplicki
Journal:  PLoS One       Date:  2010-02-24       Impact factor: 3.240

9.  Interferon induction in bovine and feline monolayer cultures by four bluetongue virus serotypes.

Authors:  R W Fulton; N J Pearson
Journal:  Can J Comp Med       Date:  1982-01

10.  Polo-like kinase 1 (PLK1) regulates interferon (IFN) induction by MAVS.

Authors:  Damien Vitour; Stéphanie Dabo; Malek Ahmadi Pour; Myriam Vilasco; Pierre-Olivier Vidalain; Yves Jacob; Mariana Mezel-Lemoine; Suzanne Paz; Meztli Arguello; Rongtuan Lin; Frédéric Tangy; John Hiscott; Eliane F Meurs
Journal:  J Biol Chem       Date:  2009-06-22       Impact factor: 5.157

View more
  21 in total

1.  NS3 of bluetongue virus interferes with the induction of type I interferon.

Authors:  Emilie Chauveau; Virginie Doceul; Estelle Lara; Emmanuel Breard; Corinne Sailleau; Pierre-Olivier Vidalain; Eliane F Meurs; Stéphanie Dabo; Isabelle Schwartz-Cornil; Stéphan Zientara; Damien Vitour
Journal:  J Virol       Date:  2013-05-08       Impact factor: 5.103

2.  Type I interferon limits the capacity of bluetongue virus to infect hematopoietic precursors and dendritic cells in vitro and in vivo.

Authors:  Teresa Rodríguez-Calvo; José-Manuel Rojas; Verónica Martín; Noemí Sevilla
Journal:  J Virol       Date:  2013-10-30       Impact factor: 5.103

3.  Activation of TLR3/interferon signaling pathway by bluetongue virus results in HIV inhibition in macrophages.

Authors:  Ming Dai; Xu Wang; Jie-Liang Li; Yu Zhou; Ming Sang; Jin-Biao Liu; Jian-Guo Wu; Wen-Zhe Ho
Journal:  FASEB J       Date:  2015-08-21       Impact factor: 5.191

4.  Virus-induced autophagic degradation of STAT2 as a mechanism for interferon signaling blockade.

Authors:  Miguel Avia; José M Rojas; Lisa Miorin; Elena Pascual; Piet A Van Rijn; Verónica Martín; Adolfo García-Sastre; Noemí Sevilla
Journal:  EMBO Rep       Date:  2019-10-11       Impact factor: 8.807

5.  Novel Function of Bluetongue Virus NS3 Protein in Regulation of the MAPK/ERK Signaling Pathway.

Authors:  Damien Vitour; Grégory Caignard; Cindy Kundlacz; Marie Pourcelot; Aurore Fablet; Rayane Amaral Da Silva Moraes; Thibaut Léger; Bastien Morlet; Cyril Viarouge; Corinne Sailleau; Mathilde Turpaud; Axel Gorlier; Emmanuel Breard; Sylvie Lecollinet; Piet A van Rijn; Stephan Zientara
Journal:  J Virol       Date:  2019-07-30       Impact factor: 5.103

6.  Early Events in Reovirus Infection Influence Induction of Innate Immune Response.

Authors:  Andrew T Abad; Pranav Danthi
Journal:  J Virol       Date:  2022-07-06       Impact factor: 6.549

7.  RIG-I Mediates an Antiviral Response to Crimean-Congo Hemorrhagic Fever Virus.

Authors:  Jessica R Spengler; Jenish R Patel; Ayan K Chakrabarti; Marko Zivcec; Adolfo García-Sastre; Christina F Spiropoulou; Éric Bergeron
Journal:  J Virol       Date:  2015-07-29       Impact factor: 5.103

8.  An updated review on bluetongue virus: epidemiology, pathobiology, and advances in diagnosis and control with special reference to India.

Authors:  Mani Saminathan; Karam Pal Singh; Jaynudin Hajibhai Khorajiya; Murali Dinesh; Sobharani Vineetha; Madhulina Maity; At Faslu Rahman; Jyoti Misri; Yashpal Singh Malik; Vivek Kumar Gupta; Raj Kumar Singh; Kuldeep Dhama
Journal:  Vet Q       Date:  2020-12       Impact factor: 3.320

9.  Dual modulation of type I interferon response by bluetongue virus.

Authors:  Virginie Doceul; Emilie Chauveau; Estelle Lara; Emmanuel Bréard; Corinne Sailleau; Stéphan Zientara; Damien Vitour
Journal:  J Virol       Date:  2014-07-09       Impact factor: 5.103

10.  RNA interference targets arbovirus replication in Culicoides cells.

Authors:  Esther Schnettler; Maxime Ratinier; Mick Watson; Andrew E Shaw; Melanie McFarlane; Mariana Varela; Richard M Elliott; Massimo Palmarini; Alain Kohl
Journal:  J Virol       Date:  2012-12-26       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.